Overview

Differential EFfects of Dual antIplatelet and Dual aNtithrombotic thErapy on Hemostasis in Chronic Coronary Syndrome Patients

Status:
Not yet recruiting

Trial end date:
2023-01-01

Target enrollment:

Participant gender:

Summary

The investigators will be comparing the effects of two different drug treatment strategies, in patients with history of a heart attack, on different markers of bleeding and clotting risk. Both treatment strategies are already approved for the indication of improving outcomes in high-risk patients with history of heart attack.

Phase:

Phase 4

Details

Lead Sponsor:

Nova Scotia Health Authority

Treatments:

Rivaroxaban
Ticagrelor